Lincoln Pharma

₹574.4 22.5 | 4.1%

WEBSITE BSE:531633 NSE : LINCOLN PHAR 10 May, 16:01

Market Cap ₹1151 Cr.

Stock P/E 13.2

P/B 2

Current Price ₹574.4

Book Value ₹ 286.6

Face Value 10

52W High ₹754.3

Dividend Yield 0.26%

52W Low ₹ 365.4

Edit Ratio

Lincoln Pharma Research see more...

Overview Inc. Year: 1995Industry: Pharmaceuticals & Drugs

Lincoln Pharmaceuticals Ltd (LPL) is engaged inside the business of producing, advertising and marketing and distribution of pharmaceutical merchandise. The Company operates through the Pharmaceuticals Products phase. The Company gives products, along with tablets, drugs, liquid injection, cream in tubes, dry power injection, liquid injection, and pharma products. It has operations in cardiac, diabetic, anti-malarial, anti-biotics, cephalosporins, analgesic, antipyretics, diet-minerals and iron preparations, among others. Its geographical segments consist of Domestic Sales and Export Sales. Its products include Tinnex, which is a remedy for treating cochlear synaptic tinnitus; Pa 12 Proglet, that is a 1000 milligram programmed released paracetamol that is developed to offer control of ache and fever, and ARH 1, that's an anti-malarial drug that is formulated using technology known as dose optimization technology.

Lincoln Pharma Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Lincoln Pharma Quarterly Results

#(Fig in Cr.)	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023
Net Sales	127	120	103	123	141	134	112	136	156	146
Other Income	3	3	2	6	6	6	4	8	9	11
Total Income	131	123	104	130	146	140	116	143	165	157
Total Expenditure	98	96	85	107	112	107	96	115	125	117
Operating Profit	33	26	19	23	35	33	21	28	40	41
Interest	0	0	1	0	0	0	1	0	0	0
Depreciation	2	2	2	2	2	2	2	3	3	3
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	31	24	17	21	32	31	17	25	37	38
Provision for Tax	8	6	6	6	8	9	4	6	9	10
Profit After Tax	23	18	11	15	24	22	13	19	28	28
Adjustments	0	0	-0	-0	0	-0	0	-0	0	0
Profit After Adjustments	23	18	11	15	24	22	13	19	28	28
Adjusted Earnings Per Share	11.5	8.8	5.5	7.5	11.8	10.8	6.3	9.5	13.8	14

Lincoln Pharma Profit & Loss

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	TTM
Net Sales	195	210	266	400	360	361	366	386	424	472	510	550
Other Income	6	2	7	7	3	5	6	11	6	10	22	32
Total Income	201	213	273	408	363	366	372	398	430	482	533	581
Total Expenditure	179	190	240	360	314	308	299	321	337	377	421	453
Operating Profit	22	23	33	48	50	58	73	77	93	105	112	130
Interest	8	7	8	10	7	5	4	2	2	1	2	1
Depreciation	3	4	5	5	6	6	7	7	8	8	9	11
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	11	12	20	33	37	46	62	67	84	96	100	117
Provision for Tax	2	2	5	9	9	12	13	16	21	27	28	29
Profit After Tax	10	10	15	24	28	35	49	51	62	69	73	88
Adjustments	0	0	-0	-0	-0	-0	-0	-0	0	0	0	0
Profit After Adjustments	10	11	15	24	28	35	49	51	62	69	73	88
Adjusted Earnings Per Share	5.9	6.5	9.2	14.5	14.1	17.3	24.4	25.7	31.1	34.6	36.4	43.6

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	8%	10%	7%	10%
Operating Profit CAGR	7%	13%	14%	18%
PAT CAGR	6%	13%	16%	22%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	47%	22%	27%	29%
ROE Average	16%	17%	18%	16%
ROCE Average	22%	24%	23%	19%

Lincoln Pharma Balance Sheet

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Shareholder's Funds	89	99	111	141	192	224	269	313	366	433	502
Minority's Interest	4	4	3	0	0	0	0	0	0	0	0
Borrowings	17	19	25	24	12	7	2	1	0	0	0
Other Non-Current Liabilities	8	7	8	10	19	18	27	42	26	11	38
Total Current Liabilities	118	131	114	100	99	113	100	80	95	111	96
Total Liabilities	237	260	262	275	324	363	399	437	487	555	637
Fixed Assets	65	65	66	98	103	117	121	123	111	132	151
Other Non-Current Assets	49	46	15	29	32	20	39	51	49	50	95
Total Current Assets	123	149	181	147	190	227	239	263	328	373	391
Total Assets	237	260	262	275	324	363	399	437	487	555	637

Lincoln Pharma Cash Flow

#(Fig in Cr.)	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Opening Cash & Cash Equivalents	12	9	5	4	3	3	7	5	12	11	7
Cash Flow from Operating Activities	-16	5	25	45	25	27	53	75	69	76	39
Cash Flow from Investing Activities	-16	1	7	-42	-25	-12	-18	-31	-64	-78	-37
Cash Flow from Financing Activities	29	-11	-32	-3	0	-11	-36	-38	-6	-3	-5
Net Cash Inflow / Outflow	-3	-4	-1	-0	-0	3	-1	7	-1	-5	-2
Closing Cash & Cash Equivalent	9	5	4	3	3	7	5	12	11	7	5

Lincoln Pharma Ratios

#	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Earnings Per Share (Rs)	5.92	6.53	9.2	14.52	14.06	17.31	24.36	25.72	31.08	34.63	36.4
CEPS(Rs)	7.47	8.41	12.02	17.57	16.82	20.38	27.71	29.4	34.85	38.66	40.97
DPS(Rs)	0.6	0.6	1	1	1.2	1.5	1.5	1.5	1.5	1.5	1.5
Book NAV/Share(Rs)	54.75	60.58	68.24	81.52	96.19	112.11	134.67	156.54	182.92	216.12	250.86
Core EBITDA Margin(%)	7.8	9.34	9.44	9.98	12.79	14.47	17.83	16.4	19.88	19.23	16.74
EBIT Margin(%)	9.69	8.86	10.4	10.6	12.04	14.28	17.55	17.33	19.45	19.61	19.24
Pre Tax Margin(%)	5.74	5.62	7.32	8.14	10.22	12.79	16.49	16.83	19.09	19.32	18.86
PAT Margin (%)	4.81	4.74	5.54	5.86	7.7	9.58	12.92	12.88	14.19	13.97	13.68
Cash Profit Margin (%)	6.14	6.38	7.23	7.06	9.21	11.27	14.7	14.71	15.92	15.6	15.4
ROA(%)	4.25	4.1	5.77	8.87	9.4	10.09	12.8	12.33	13.48	13.31	12.24
ROE(%)	11.21	10.83	14.32	19.49	17.29	16.63	19.75	17.67	18.32	17.35	15.59
ROCE(%)	12.21	11.48	15.91	21.18	18.51	19.05	22.5	22.3	24.9	24.29	21.82
Receivable days	128.96	139.16	139.97	89.69	85.52	100.99	112.23	102.22	89.34	84.27	86.41
Inventory Days	37.48	36.67	30.72	22.16	32.36	41.74	39.51	38.19	39.12	43.86	48.9
Payable days	143.42	168.2	126.66	54.24	56.51	88.51	117.62	125.84	126.82	138.44	124.92
PER(x)	4.05	6.38	8.52	10.83	16.78	12.15	8.73	5.2	7.23	8.98	9.31
Price/Book(x)	0.44	0.69	1.15	1.93	2.45	1.88	1.58	0.85	1.23	1.44	1.35
Dividend Yield(%)	2.5	1.44	1.28	0.64	0.51	0.71	0.71	1.12	0.67	0.48	0.44
EV/Net Sales(x)	0.51	0.6	0.72	0.8	1.46	1.3	1.23	0.67	1.03	1.28	1.27
EV/Core EBITDA(x)	4.55	5.57	5.88	6.72	10.6	8.09	6.19	3.37	4.7	5.75	5.79
Net Sales Growth(%)	3.8	8.11	26.41	50.39	-9.97	0.1	1.53	5.56	9.75	11.3	8.09
EBIT Growth(%)	28.79	-0.95	48.22	52.45	2.25	17.42	28.13	4.62	23.15	14.2	5.26
PAT Growth(%)	85.92	6.82	47.69	58.23	18.21	23.16	40.66	5.6	20.95	11.41	5.11
EPS Growth(%)	88.73	10.27	40.9	57.75	-3.15	23.11	40.69	5.6	20.84	11.41	5.11
Debt/Equity(x)	0.85	0.69	0.69	0.59	0.34	0.27	0.12	0.02	0	0	0
Current Ratio(x)	1.04	1.14	1.58	1.46	1.91	2	2.38	3.27	3.46	3.37	4.07
Quick Ratio(x)	0.88	0.96	1.39	1.19	1.55	1.61	2.03	2.68	2.97	2.71	3.34
Interest Cover(x)	2.45	2.73	3.37	4.32	6.6	9.55	16.56	34.32	54.61	67.11	50.5
Total Debt/Mcap(x)	1.93	1	0.6	0.3	0.14	0.15	0.08	0.02	0	0	0

Lincoln Pharma Shareholding Pattern

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	42.08	42.05	44.08	44.08	46.34	47	48.67	50.53	49.8	49.53
FII	0.95	0.77	0.64	0.64	1.44	1.27	1.74	2.59	3.23	3.93
DII	0	0	0	0	0	0	0	0	0.06	0.05
Public	56.97	57.19	55.28	55.28	52.22	51.73	49.58	46.88	46.91	46.49
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024
Promoter	0.84	0.84	0.88	0.88	0.93	0.94	0.97	1.01	1	0.99
FII	0.02	0.02	0.01	0.01	0.03	0.03	0.03	0.05	0.06	0.08
DII	0	0	0	0	0	0	0	0	0	0
Public	1.14	1.15	1.11	1.11	1.05	1.04	0.99	0.94	0.94	0.93
Others	0	0	0	0	0	0	0	0	0	0
Total	2	2	2	2	2	2	2	2	2	2

Pros

Debtor days have improved from 138.44 to 124.92days.
Company is almost debt free.

Cons

Promoter holding is low: 49.53%.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Lincoln Pharma News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Lincoln Pharma

Add Watchlist

Lincoln Pharma Research see more...

Overview Inc. Year: 1995Industry: Pharmaceuticals & Drugs

Lincoln Pharma Share Price

Alert Data

Quarterly Price

Peer Comparison

Lincoln Pharma Quarterly Results

Lincoln Pharma Profit & Loss

Growth Rates

Lincoln Pharma Balance Sheet

Lincoln Pharma Cash Flow

Lincoln Pharma Ratios

Lincoln Pharma Shareholding Pattern

Lincoln Pharma News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!